ClinicalTrials.gov
public full text
Public Domain
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
acute-respiratory-distress-syndromecoronavirus-infectionscovid-19respiratory-tract-diseasesvirus-diseases
It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Inflammatory Regulation Effect of NAC on COVID-19 Treatment#826937
- Tolerability and Efficacy of RJX in Patients With COVID-19#1096178
- Predicting severe COVID-19 in elderly patients using routine laboratory indicators: Diagnostic accuracy of machine learning models.#388717
- Risk Identification of Long-term Complications#1153758
- Demonstration of Interoperability Between MIDRC and N3C: A COVID-19 Severity Prediction Use Case.#258394
Record · ID 969864
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive